Dr. Brian G.M. Durie discusses important takeaways relating to multiple myeloma from the annual American Society of Hematology (ASH) conference
Of the 4,140 abstracts presented at the 2021 ASH meeting, 879 were multiple myeloma-related. In this "Best of ASH 2021" webinar, IMF Chairman of the Board Dr. Brian G.M. Durie highlights the top myeloma abstracts presented during the annual conference that discuss the following topics:
- A new look at early disease: MGUS & SMM
- Minimal residual disease monitoring
- Frontline therapy with four drug combinations
- Immune therapies, including CAR T-cell therapies and bispecifics
- Emerging new treatments
Dr. Durie explains this data in approachable terms that patients and caregivers can use in their everyday care decision-making. You won’t want to miss this key webinar.
With Support from:
Amgen, Bristol-Myers Squibb, Janssen Oncology, Karyopharm Therapeutics, Oncopeptides, Takeda Oncology
